Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

80.33 -1.01 (-1.24%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

December 01, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 14, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 13, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Earnings Preview ↗

October 28, 2025

Via Benzinga

Ionis to present at upcoming investor conferences

November 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.

Via Benzinga

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 11, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗

November 10, 2025

Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

November 08, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

November 06, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...

Via Benzinga

Ionis (IONS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Ionis (IONS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 30, 2025

Via Benzinga

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 29, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

October 27, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

October 23, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

October 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

Ionis to hold third quarter 2025 financial results webcast

October 16, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength ↗

October 15, 2025

IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.